<DOC>
	<DOCNO>NCT00852020</DOCNO>
	<brief_summary>To test compliance , tolerance , safety get preliminary insight efficacy new oral nutritional supplement ( contain n-3 fatty acid , amino acid antioxidant ) design prevent delay cachexia anorexia patient chronic heart failure ( CHF ) chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>Safety , Tolerance Efficacy Oral Nutritional Supplement Chronic Heart Failure Chronic Obstructive Pulmonary Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<criteria>diagnosis CHF COPD current body weight less 6 month ago BMI &gt; =20 &lt; =30 kg/m2 CHF : LVEF &gt; =45 % measure within past 6 month symptom status equivalent NYHA class II IV biochemical abnormality total cholesterol , serum uric acid , abnormal high CRP standard therapy CHF include ACE inhibitor beta blocker COPD : symptom status equivalent GOLD standard class II IV FEV1 &lt; 80 % FEV1/FEV &lt; 70 % significant oedema time screen randomisation concomitant inflammatory disease active infection include HIV AIDS liver failure chronic renal failure ( sCr &gt; 1.5mg/dL ) cardiac pacemaker acute chronic infection insulin treat diabetes mellitus patient establish diagnosis cachexia life expectancy le 6 month opinion investigator medication impair sex hormone synthesis , secretion function patient psychiatric disease body weight loss &gt; 5 % last 6 month &gt; 10 % last 10 month suspect allergy component investigational product ( ) fish oil supplementation within 3 month prior study entry take vitamin supplement dose great Recommended Daily Allowances</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>